期刊文献+

mFOLFOX6方案治疗晚期结肠癌疗效分析 被引量:4

Effect of mFOLFOX6 regimen as salvage chemotherapy for patients with advanced colon cancer
暂未订购
导出
摘要 目的:临床观察mFOLFOX6方案治疗21例晚期结肠癌的近期疗效、临床获益率和不良反应。方法:采用mFOLOFX6方案(奥沙利铂85mg/m^2静滴2小时第1天;亚叶酸钙400mg静滴2小时第1天;;5-FU400mg/m^2静冲第1天;5-FU2.4g/m^2持续静滴44小时)每两周给药。3周期化疗后观察客观缓解率、临床获益率和不良反应。结果:21例患者总有效率为47.6%。CR1例(4.8%),PR9例(42.9%),SD6例(28.6%),临床获益率为76.2%。主要不良反应是消化道反应,1-2度消化道不良反应13例(61.9%)。Ⅲ-Ⅳ度血液学毒性3例(14.3%)。结论:mFOLOFX6方案治疗晚期结肠癌是安全、有效的。 Objective: To investigate the efficacy and safety of mFOLFOX6 as first - line regimen for patients with advanced colon cancer. Methods: Twenty -one patients with advanced colon cancer were treated by mFOLFOX6 regimen of 3 cycles. Results: Of the 21 patients,the overall response rate was 47.6% ,complete response rate was 4. 8% ,partial response rate was 42.9% ,clinical benefit rate was 76.2%. The major toxicity was nausea vomiting. In cidences of neutroponia of grade Ⅲ - Ⅳ was 14.3%. Conclusion: mFOLFOX6 is a safe and effective regimen in advanced colon cancer.
出处 《现代肿瘤医学》 CAS 2010年第7期1374-1375,共2页 Journal of Modern Oncology
关键词 晚期结肠癌 MFOLFOX6 客观疗效 mFOLFOX6 advanced colon cancer therapeutic effect
  • 相关文献

参考文献4

  • 1Jemal A,Siegel.Cancer atatistics,2009[J].CA Cancer J Clin,2009,59:225-229.
  • 2Cheeseman S,Joel S,Chester J,et al.A"modified de Gramont"regimen of fluorouracil,alone and with oxaliplatin,for advanced colorectal cancer[J].Brit J Cancer,2002,87:393-399.
  • 3Welles L,Hochster H,Ramanathan R et al.Preliminary results of a randomized study of aafety and tolerability of three oxaliplatinbased regimens as first-line treatment for advanced colorectal cancer[J].J Clin Oncol,2004,2:3.
  • 4徐瑞华,邱妙珍.晚期结直肠癌化疗的研究进展[J].癌症,2008,27(6):661-666. 被引量:51

二级参考文献37

  • 1Cats A. New development in systemic chemotherapy in advanced colorectal cancer [J]. Seand J Gastroenterol Suppl, 2003, (239) : 78-86.
  • 2The Advanced Colorectal Cancer MetaAnalysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate [J]. J Clin Oncol, 1992,10(6) : 896-903.
  • 3Poon M A, O'Connell M J, Wieand H S, et al. Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer [J]. J Clin Oncol, 1991,9(11):1967- 1972.
  • 4de Gramont A, Bosset J F, Milan C, et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly highdose leucovorin and fluoronracil bolus plus continuous infusion for advanced colorectal cancer: a French Intergroup study [J]. J Clin Oncol, 1997,15(2): 808-815.
  • 5Machover D, Diaz-Rubio E, de Gramont A, et al. Two consecutive phase Ⅱ studies of oxaliplatin (LOHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluorepyrimidines [J]. Ann Oncol, 1996,7( 1 ) :95-98.
  • 6Becouarn Y, Ychou M, Ducreux M, et al. Phase H trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of Cancer Centers [J]. J Clin Oncol, 1998,16 ( 8 ) : 2739-2744.
  • 7Giacchetti S, Perpoint B, Zidani R, et al. Phase Ⅲ muhicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer [J]. J Clin Oncol, 2000,18( 1 ) : 136-147.
  • 8de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer [J]. J Clin Oncol, 2000,18(16): 2938-2947.
  • 9Conti J A, Kemeny N E, Saltz L B,et al. Irinotecan is an active agent in untreated patients with metastatic colorectal cancer [J]. J Clin Oncol, 1996, 14(3) :709-715.
  • 10Pitot H C, Wender D B, O'Connell M J, et al. Phase Ⅱ trial of irinotecan in patients with metastatic colorectal carcinoma [J]. J Clin Oncol, 1997, 15(8) :2910-2919.

共引文献50

同被引文献34

  • 1杨学宁,吴一龙.实体瘤治疗疗效评价标准——RECIST[J].循证医学,2004,4(2):85-90. 被引量:1840
  • 2吕洋,赵坡.大肠癌383例的临床病理及预后分析[J].中华肿瘤防治杂志,2007,14(8):613-616. 被引量:17
  • 3Lochan R, White SA, Manas DM. Liver resection for colorectal liver metastasis [ J ] Surg Onco1,2007,16 ( 1 ) :33 - 45.
  • 4Pawlik TM, Choti MA. Surgical therapy for colorectal metastases to the liver[ J ]. J Gastrointest Surg,2007,11 (8) : 1057 - 1077.
  • 5Mandala M, Mosconi S, Quadri A, et al. Neoadjuvant chemotherapyfor patients with liver metastases from colorectal cancer[ J]. Expert Rev Anticancer Ther,2007,7 ( 6 ) :887 - 897.
  • 6Sylvain Manfredi, Co me Lepage. Epidemiology and management of liver metastases from colorectal cancer [ J ]. Ann Surg, 2007,244 (2) :254-259.
  • 7MeMillan DC, McArdle CS. Epidemiology of eolorectal liver metas- tases [ J ]. Surg Oneo1,2007,16 (1) :3 - 5.
  • 8Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advancedcotarectal cancer:a randomized GERCOR study [ J ]. J Clin Oncol, 2004,22 ( 2 ) : 229 - 237.
  • 9Omura K. Advances in chemotherapy against advanced or metastati- ce coloreetal cancer[ J]. Digestion,2008,77 ( Suppl 1 ) : 13 - 22.
  • 10Gregory DL, Baruch B, Nancy EK. Neoadjuvant chemotherapy be- fore liver resection for patients with unresectable livermetastases from colorectal carcinoma [ J ]. J Clin Oncol, 2005,23:2038 - 2048.

引证文献4

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部